Literature DB >> 16270626

Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients.

Alexander T Cohen1, Raza Alikhan, Juan I Arcelus, Jean-François Bergmann, Sylvia Haas, Geno J Merli, Alex C Spyropoulos, Victor F Tapson, Alexander G G Turpie.   

Abstract

Hospitalized patients with acute medical conditions are at significant risk of venous thromboembolism (VTE): approximately 10-30% of general medical patients may develop deep-vein thrombosis or pulmonary embolism, and the latter is a leading contributor to deaths in hospital. Despite consensus-group recommendations that at-risk medical patients should receive thromboprophylaxis, there is currently no consensus as to which patients are at risk, and many patients may not receive appropriate thromboprophylaxis. This paper reviews evidence for the risk of VTE associated with different medical conditions and risk factors, and presents a risk-assessment model for risk stratification in medical patients. Medical conditions associated with a moderate to high risk of VTE include cardiac disease, cancer, respiratory disease, inflammatory bowel disease, and infectious diseases. Importantly, analyses of data from the MEDENOX study show that thromboprophylaxis significantly reduces the risk of VTE in these patient subgroups. Risk factors in medical patients include a history of VTE, history of malignancy, increasing age, thrombophilia, prolonged immobility, and obesity. These medical conditions and risk factors are included in a risk-assessment model which is hoped will provide a simple means of assisting clinicians in deciding whether thromboprophylaxis should be used in an individual patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16270626

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  59 in total

Review 1.  Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing.

Authors:  Charles E Mahan; Mario Pini; Alex C Spyropoulos
Journal:  Intern Emerg Med       Date:  2010-02-23       Impact factor: 3.397

2.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Venous thromboembolism in COPD hospitalized patients.

Authors:  Raquel Barba; Antonio Zapatero; Javier Marco; Juan E Losa; Susana Plaza; Jose Manuel Casas; Jesús Canora
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

4.  Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.

Authors:  Megan K Yee; Tarek Nafee; Yazan Daaboul; Serge Korjian; Fahad AlKhalfan; Mathieu Kerneis; Cara Wiest; Samuel Z Goldhaber; Adrian F Hernandez; Russell D Hull; Alexander T Cohen; Robert A Harrington; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

5.  Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2011.

Authors:  K Walenta; J M Sinning; N Werner; M Böhm
Journal:  Clin Res Cardiol       Date:  2011-04-23       Impact factor: 5.460

6.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

7.  The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty.

Authors:  Janet N Chu; Judith Maselli; Andrew D Auerbach; Margaret C Fang
Journal:  Thromb Res       Date:  2017-04-12       Impact factor: 3.944

Review 8.  Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.

Authors:  Kayla M Miller; Michael J Brenner
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 9.  Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.

Authors:  Anna K Jönsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

10.  Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients?

Authors:  R Kreidy; N Irani-Hakime
Journal:  Vasc Health Risk Manag       Date:  2009-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.